Health and Fitness Health and Fitness
Sat, September 24, 2011
[ Sat, Sep 24th 2011 ] - Market Wire
Millennium et Seattle Genetics pr©sentent, .. r©union annuelle de la?EMCC,;;; des
[ Sat, Sep 24th 2011 ] - Market Wire
Millennium et Seattle Genetics pr©sentent la?occ .. e la?EMCC des donn©es cliniques concernant la?ut
[ Sat, Sep 24th 2011 ] - Market Wire
Millennium und Seattle Genetics legen auf der EMC .. n zu ADCETRISa" (Brentuximab Vedotin) bei pdiatri
[ Sat, Sep 24th 2011 ] - Market Wire
Millennium et Seattle Genetics pr©sentent, la?oc .. de la?EMCC, des donn©es cliniques concernant la?
[ Sat, Sep 24th 2011 ] - Market Wire
Millennium and Seattle Genetics Present Clinical .. mab Vedotin) in Pediatric Patients at EMCC Annual
Fri, September 23, 2011
[ Fri, Sep 23rd 2011 ] - Market Wire
Law Office of Brodsky & Smith, LLC Announces Investigation of American Medical Alert Corp.
[ Fri, Sep 23rd 2011 ] - Market Wire
Tunstall Healthcare Group Limited vor bernahme von AMAC, American Medical Alert Corp.
[ Fri, Sep 23rd 2011 ] - Market Wire
U.S. Health & Human Services Makes Critical Conge .. Using Motion-Tolerant Pulse Oximetry a Nationwide
[ Fri, Sep 23rd 2011 ] - Market Wire
Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings
[ Fri, Sep 23rd 2011 ] - Market Wire
Delcath Announces Updated Efficacy Results From P .. on for Melanoma Metastases in the Liver Presented
[ Fri, Sep 23rd 2011 ] - Market Wire
Unilife CEO to Purchase an Additional U.S. $500,000 in Company Shares by September 30, 2011
[ Fri, Sep 23rd 2011 ] - Market Wire
Europese CHMP geeft een positieve mening over Evi .. el-tablet regime voor de behandeling van HIV-infe
[ Fri, Sep 23rd 2011 ] - Market Wire
Alexion obtient un avis favorable du Comit© des .. ) pour le Soliris® (eculizumab) dans le traiteme
[ Fri, Sep 23rd 2011 ] - Market Wire
Alexion erhlt positive CHMP-Stellungnahme fr Soli .. ung von Patienten mit atypischem hmolytisch-urmis
[ Fri, Sep 23rd 2011 ] - Market Wire
CHMP recomienda (APEL) DIFICLIRa" de Astellas Pharma Europe Ltd para aprobacin en la UE
[ Fri, Sep 23rd 2011 ] - Market Wire
Le CHMP recommande l'approbation de DIFICLIRa", d .. arma Europe Ltd. (APEL), dans l'Union europ©enne
[ Fri, Sep 23rd 2011 ] - Market Wire
Faruqi & Faruqi, LLP Announces Investigation of American Medical Alert Corp.
[ Fri, Sep 23rd 2011 ] - Market Wire
Law Offices of Howard G. Smith LLP Announces Investigation of American Medical Alert Corp
[ Fri, Sep 23rd 2011 ] - Market Wire
Tunstall Healthcare Group Limited comprar a AMAC, American Medical Alert Corp.
[ Fri, Sep 23rd 2011 ] - Market Wire
El Comit© de Medicamentos de Uso Humano europeo .. era®, un tratamiento de comprimido nico y admini
[ Fri, Sep 23rd 2011 ] - Market Wire
Il Comitato europeo per i prodotti medicinali per .. icinal Products for Human Use CHMP) adotta un par
[ Fri, Sep 23rd 2011 ] - Market Wire
Il Comitato europeo per i prodotti medicinali per .. icinal Products for Human Use, CHMP) adotta un pa
[ Fri, Sep 23rd 2011 ] - Market Wire
Alexion riceve il parere positivo nell'UE da part .. izumab) per il trattamento di pazienti affetti da
[ Fri, Sep 23rd 2011 ] - Market Wire
CytoDyn Announces Humanized Cytolin® Provisional .. t Application Filed for the Treatment of HIV/AIDS
[ Fri, Sep 23rd 2011 ] - Market Wire
Rigrodsky & Long, P.A. Announces Investigation of American Medical Alert Corp.
[ Fri, Sep 23rd 2011 ] - Market Wire
Soliris® (eculizumab) approvato dalla FDA per tu .. fetti da sindrome emolitico uremica (SEU) atipica
[ Fri, Sep 23rd 2011 ] - Market Wire
Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Allos Therapeutics, Inc.
[ Fri, Sep 23rd 2011 ] - Market Wire
Alexion ontvangt positieve CHMP-aanbeveling voor .. nten met atypisch hemolytisch uremisch syndroom i
[ Fri, Sep 23rd 2011 ] - Market Wire
Soliris (eculizumab) goedgekeurd door FDA voor al .. met atypisch hemolytisch uremisch syndroom (aHUS)
[ Fri, Sep 23rd 2011 ] - Market Wire
Celgene: reglementaire update inzake REVLIMID

Celgene: reglementaire update inzake REVLIMID


Published on 2011-09-23 12:04:00 - Market Wire
  Print publication without navigation


BOUDRY, Switzerland--([ BUSINESS WIRE ])--Celgene International Srl (NASDAQ: CELG) is ervan op de hoogte gesteld, dat het EU-Comit© voor Medicijnproducten voor Menselijk Gebruik (CHMP) in naam van het European Medicines Agency (EMA) een Artikel 20-herziening van REVLIMID heeft afgesloten en een positief advies afgeeft voor het gebruik van REVLIMID in combinatie met dexamethasone voor de behandeling van patinten met meervoudig myeloom, die tenminste ©©n eerdere therapie ondergingen. De Artikel 20-procedure werd genitieerd na meldingen van een klein aantal gevallen van tweede primaire tumoren bij klinisch onderzoek.

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal welke als enige juridische geldigheid beoogt.

Contributing Sources